Exhibit 12

E. I. DU PONT DE NEMOURS AND COMPANY

COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(Dollars in millions)

	Nine Months
	Ended
	September 30,			Years Ended December 31,
	2006			2005			2004			2003			2002			2001
Income before cumulative effect of changes in accounting principles	$	2,277		$	2,053		$	1,780		$	1,002		$	1,841		$	4,328	(a)
Provision for (benefit from) income taxes		662			1,468			(329	)		(930	)		185			2,467
Minority interests in earnings (losses) of consolidated subsidiaries		2			37			(9	)		71			98			49
Adjustment for companies accounted for by the equity method		90			215			99			360			45			93
Capitalized interest		(26	)		(23	)		(17	)		(29	)		(45	)		(62	)
Amortization of capitalized interest		25			33			365	(b)		119	(b)		59			61
		3,030			3,783			1,889			593			2,183			6,936
Fixed charges:
Interest and debt expense		347			518			362			347			359			590
Capitalized interest		26			23			17			29			45			62
Rental expense representative of interest factor		66			88			91			90			82			78
		439			629			470			466			486			730
Total adjusted earnings available for payment of fixed charges	$	3,469		$	4,412		$	2,359		$	1,059		$	2,669		$	7,666
Number of times fixed charges earned		7.9			7.0			5.0			2.3			5.5			10.5

(a)	Includes $3,866 after-tax gain on the sale of DuPont Pharmaceuticals to Bristol-Myers Squibb.
(b)	Includes write-off of capitalized interest associated with exiting certain businesses.